nurulimab

Home
Ligands
nurulimab

GtoPdb Ligand ID: 12992

Synonyms: BCD-145 | BCD145

Comment: Nurulimab (BCD-145) is a human IgG1 anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) monoclonal antibody. It blocks the interaction between CTLA4 and its ligands CD80 and CD86, which establishes an inhibitory immune checkpoint. Blocking this checkpoint offers therapeutic potential as this mechanism stimulates the immune system to destroy cancer cells.

Summary
Biological activity
Clinical data
References
Immunopharmacology

No information available.

No information available.

Summary of Clinical Use
Nurulimab (BCD-145) is in clinical development. It is also being evaluated for efficacy in combination with the anti-PD-1 candidate prolgolimab (BCD-100). The combination of BCD-100 and BCD-145 is known as BCD-217.

Summary of Clinical Use

Nurulimab (BCD-145) is in clinical development. It is also being evaluated for efficacy in combination with the anti-PD-1 candidate prolgolimab (BCD-100). The combination of BCD-100 and BCD-145 is known as BCD-217.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT03472027	Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma	Phase 1 Interventional	Biocad